These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33770104)

  • 1. Assessing the impacts of short-course multidrug-resistant tuberculosis treatment in the Southeast Asia Region using a mathematical modeling approach.
    Han WM; Mahikul W; Pouplin T; Lawpoolsri S; White LJ; Pan-Ngum W
    PLoS One; 2021; 16(3):e0248846. PubMed ID: 33770104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fighting the tuberculosis epidemic in the Western Pacific region: current situation and challenges ahead.
    van Maaren PJ
    Kekkaku; 2010 Jan; 85(1):9-16. PubMed ID: 20143671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of multidrug-resistant tuberculosis in Thailand.
    Maranetra KN
    Chemotherapy; 1996; 42 Suppl 3():10-5; discussion 30-3. PubMed ID: 8980862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan.
    Trauer JM; Achar J; Parpieva N; Khamraev A; Denholm JT; Falzon D; Jaramillo E; Mesic A; du Cros P; McBryde ES
    BMC Med; 2016 Nov; 14(1):187. PubMed ID: 27855693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eligibility for a Shorter Treatment Regimen for Multidrug-resistant Tuberculosis in the United States, 2011-2016.
    Tsang CA; Shah N; Armstrong LR; Marks SM
    Clin Infect Dis; 2020 Feb; 70(5):907-916. PubMed ID: 30944927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis.
    Kendall EA; Fojo AT; Dowdy DW
    Lancet Respir Med; 2017 Mar; 5(3):191-199. PubMed ID: 27989591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-resistant tuberculosis in the WHO Western Pacific Region.
    Islam T; Hiatt T; Hennig C; Nishikiori N
    Western Pac Surveill Response J; 2014; 5(4):34-46. PubMed ID: 25685604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis.
    Kendall EA; Azman AS; Cobelens FG; Dowdy DW
    PLoS One; 2017; 12(3):e0172748. PubMed ID: 28273116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
    Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis.
    Gao J; Ma Y; Du J; Zhu G; Tan S; Fu Y; Ma L; Zhang L; Liu F; Hu D; Zhang Y; Li X; Li L; Li Q
    BMC Pulm Med; 2016 Feb; 16():26. PubMed ID: 26846562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory-Based Surveillance of Extensively Drug-Resistant Tuberculosis in Eastern China.
    Huang Y; Wu Q; Xu S; Zhong J; Chen S; Xu J; Zhu L; He H; Wang X
    Microb Drug Resist; 2017 Mar; 23(2):236-240. PubMed ID: 27754791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis.
    Sultana ZZ; Hoque FU; Beyene J; Akhlak-Ul-Islam M; Khan MHR; Ahmed S; Hawlader DH; Hossain A
    BMC Infect Dis; 2021 Jan; 21(1):51. PubMed ID: 33430786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis.
    Eshetie S; Gizachew M; Dagnew M; Kumera G; Woldie H; Ambaw F; Tessema B; Moges F
    BMC Infect Dis; 2017 Mar; 17(1):219. PubMed ID: 28320336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
    Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC
    JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors.
    Xu C; Li R; Shewade HD; Jeyashree K; Ruan Y; Zhang C; Wang L; Zhang H
    PLoS One; 2019; 14(4):e0214943. PubMed ID: 30958841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects for advancing tuberculosis control efforts through novel therapies.
    Salomon JA; Lloyd-Smith JO; Getz WM; Resch S; Sánchez MS; Porco TC; Borgdorff MW
    PLoS Med; 2006 Aug; 3(8):e273. PubMed ID: 16866578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health.
    Telzak EE; Chirgwin KD; Nelson ET; Matts JP; Sepkowitz KA; Benson CA; Perlman DC; El-Sadr WM
    Int J Tuberc Lung Dis; 1999 Apr; 3(4):337-43. PubMed ID: 10206505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Impact of Rapid Drug Susceptibility Testing to Accompany Fluoroquinolone-Containing Universal Tuberculosis Regimens: A Markov Model.
    Kendall EA; Malhotra S; Cook-Scalise S; Dowdy DW; Denkinger CM
    Clin Infect Dis; 2020 Dec; 71(11):2889-2896. PubMed ID: 31813958
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.